CYP3A4 and non-small cell lung carcinoma: A phase I study found that the exposure (AUC) of osimertinib increased by 24% when coadministered with itraconazole (strong CYP3A4 inhibitor) and decreased by 78% when coadministered with rifampicin (CYP3A4 inducer) in patients with advanced NSCLC [4].